DEERFIELD, Ill., March 20, 2019 (GLOBE NEWSWIRE) — RTI Surgical Holdings, Inc. (NASDAQ: RTIX), a global surgical implant company, today announced it enrolled the first patient in its Clinical Evaluation of Fortilink® Interbody Fusion Device with TETRAfuse® 3D Technology in Subjects with Degenerative Disc Disease (FORTE) study. FORTE is a prospective, multicenter post-market evaluation of the safety and performance of …